| LUCID-MS: Patented new chemical entity (NCE)
Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions.
Lucid-MS has shown excellent results in several animal models.
LUCID-MS: Disease Modifying Enabling Remyelination
A sampling of the novel qualities of Lucid-MS include:
- Excellent efficacy in various preclinical animal models
- Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degradation
- Does not suppress immune system (non-immunomodulatory)
- Potential oral administration with easy dosing regimen
Quantum BioPharma has completed the dosing of healthy human volunteers for phase-1 clinical trials for Lucid-MS.
Today there is no cure for Multiple Sclerosis.
Quantum BioPharma (“QNTM”) is trying to change this for millions of people.
Grab Sources And More: QNTM Website. QNTM Presentation. -----
5 Potential Catalysts Put (Nasdaq: QNTM) On Our Immediate Radar
1.) QNTM Has A Fairly Low Float (Volatility Potential Could Be Explosive).
With a float of roughly 3.58Mn shares according to Yahoo Finance, volatility potential could be significantly heightened for QNTM on a daily basis.
2.) Kingswood Capital Partners Initiates Coverage on Quantum BioPharma Ltd. With A $45 Target.
Kingswood Capital Partners' analyst, Karen Sterling, provided a report on Quantum BioPharma Ltd. In it, she came to the conclusion (Nasdaq: QNTM) deserved a $45 target.
From Friday's closing valuation, that $45 target represents a potential upside over 400%.
3.) Another Analyst Target Suggests Triple-Digit Upside Potential.
Back in June, Singular Research analyst, Gowshihan Sriharan, updated coverage on (Nasdaq: QNTM) with a price forecast of $35.
As of close on Friday, that target suggests QNTM may have a potential upside of over 290%.
4.) Quantum BioPharma Advances Lucid-MS Toward Promising Phase 2 Clinical Trial.
Quantum BioPharma announced the completion of two pivotal toxicity studies for its potential breakthrough Multiple Sclerosis drug, Lucid-21-302 (Lucid-MS).
The final 90-day oral toxicity and toxicokinetic reports mark a major milestone, strengthening the company’s Investigational New Drug (IND) application to the U.S. FDA.
Executives highlighted the results as critical progress toward launching a Phase 2 clinical trial.
Lucid-MS aims to be a first-in-class therapy focused on repairing demyelination, showcasing Quantum BioPharma’s growing leadership in innovative neurodegenerative disease treatments.
5.) Quantum BioPharma Advances Lucid-MS Manufacturing For Upcoming Phase Two Success.
Quantum BioPharma announced a major milestone as its subsidiary, Huge Biopharma Australia, signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture the oral drug formulation of Lucid-21-302 (Lucid-MS).
This formulation will be used in the company’s upcoming Phase 2 clinical trial for Multiple Sclerosis.
Lucid-MS, a patented first-in-class neuroprotective compound, has shown promising results in animal models restoring mobility and preventing demyelination.
The partnership strengthens Quantum BioPharma’s preparation for FDA submission and demonstrates continued progress toward groundbreaking MS treatment innovation. -----
Coverage is now officially underway on Quantum BioPharma Ltd. (Nasdaq: QNTM).
When updates are available, I'll get them out quickly. Talk to you soon.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Quantum BioPharma Ltd. (QNTM:US) (QNTM:CA) previously changed their company name and symbols from FSD Pharma Inc. (HUGE:US) (QNTM:CA)
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 12/21/2025 and ending on 12/22/2025 to publicly disseminate information about (QNTM:US) (QNTM:CA) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid eight thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from Quantum BioPharma Ltd., the issuer of (QNTM:US) (QNTM:CA).
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (QNTM:US) (QNTM:CA).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/qntm-7xlxj/#details | 
0 التعليقات:
إرسال تعليق